new technologies competing with glp-1 medications 2025 Understanding GLP-1s and their dynamic marketplace and workplace trends Pharma 2025: AI, GLP-1 competition,
Description
GLP-1 treatment was safe and elicited a significant improvement in LV ejection fraction (to a mean of 39 2%) [74]
Treatment must be provided by specialist weight management services, is limited to a maximum of 2 years, and requires specific weight loss targets to continue
P., & Aroda, V
This case study highlights GLP-1s role in preventing complications that could shorten lifespan
